Showing 1641-1650 of 2314 results for "".
- Gyroscope Therapeutics Announces First Patient Dosed in Phase 2 Trial Evaluating Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-2-trial-evaluating-investigational-gene-therapy-for-dry-amd/2478523/Gyroscope Therapeutics announced the initiation of the phase 2 HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeff
- First COVID-19 Vaccine Doses To Go To Health Workers, Say CDC Advisershttps://modernod.com/news/first-covid-19-vaccine-doses-to-go-to-health-workers-say-cdc-advisers/2478502/Health care workers will almost certainly get the first doses of COVID-19 vaccine in the U.S. when one is approved, according to Dr. José Romero, head of the committee that develops evidence-based immunization guidelines for the Centers for Disease Control and Prevention, as
- UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edemahttps://modernod.com/news/unity-biotechnology-announces-first-patient-dosed-in-phase-1-study-of-ubx1325-in-diabetic-macular-edema/2478402/UNITY Biotechnology announced that the first patient has been dosed in a phase 1 study of UBX1325 in patients with diabetic macular edema (DME). “There is strong evidence of association between disease progression in DME and accumulation of senescent cells. There’s additional
- Azar Lays Out Optimistic COVID-19 Vaccine Timeline of 100 Million Doses by End of 2020https://modernod.com/news/azar-lays-out-optimistic-covid-19-vaccine-timeline-of-100-million-doses-by-end-of-2020/2478396/Health and Human Services Secretary Alex Azar was optimistic that the administration could have 100 million doses of a COVID-19 vaccine by the end of the year but did not promise a vaccine approval before election day, according to a FierceHealthcare
- Ocular Therapeutix Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-first-patients-dosed-in-phase-2-clinical-trial-of-otx-csi-for-the-treatment-of-dry-eye-disease/2478343/Ocular Therapeutix announced that it has dosed the first patients in its hase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease. “Having successfully completed the phase 1 study, we are excited to have recently begun dosing patients in
- Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-selects-0-1-ncx-470-dose-in-adaptive-stage-of-mont-blanc-phase-3-glaucoma-trial/2478316/Nicox SA announced the selection of the 0.1% dose of NCX 470 for phase 3 following the completion of the adaptive portion of the Mont Blanc phase 3 clinical trial. As is customary for adaptive design trials, in order to maintain the integrity of the trial, no data from the adaptive portion of the
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o
- Aura Biosciences Doses First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanomahttps://modernod.com/news/aura-biosciences-doses-first-patient-in-phase-2-study-evaluating-suprachoroidal-administration-of-au-011-in-patients-with-choroidal-melanoma/2478272/Aura Biosciences announced the dosing of the first patient in a phase 2 study evaluating the safety and efficacy of suprachoroidal (SC) administration of AU-011, the company’s lead product candidate, as a potential first-line treatment for patients with primary choroidal melanoma. “I am ho
- Clearside Biomedical’s Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjectorhttps://modernod.com/news/clearside-biomedicals-partner-doses-first-patient-in-its-phase-2-study-in-patients-with-choroidal-melanoma-using-scs-microinjector/2478269/Clearside Biomedical announced that its licensing partner, Aura Biosciences, has dosed the first patient in its phase 2 clinical trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroi
- Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd/2478257/Regenxbio announced that the first patient has been dosed in the AAVIATE trial, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (AMD). The company expects to report interim data from the first